Eli Lil­ly notch­es an­oth­er pos­i­tive baric­i­tinib eczema tri­al, but has Der­mi­ra made it ob­so­lete?

En­ter­ing to­day, most of what you need­ed to know about Eli Lil­ly’s JAK in­hibitor baric­i­tinib could be found in two places:

In the FDA-man­dat­ed, 1,000-plus word, bold­ed note now ap­pend­ed to the end of every press re­lease about the drug that be­gins: “WARN­ING: SE­RI­OUS IN­FEC­TIONS, MA­LIG­NAN­CY, AND THROM­BO­SIS.”

And in the run-up to the JP Mor­gan Health­care Con­fer­ence, when Eli Lil­ly dropped $1.1 bil­lion on the an­ti-in­flam­ma­to­ry skin biotech Der­mi­ra – a move that SVB Leerink’s Pasha Sar­raf had pre­dict­ed a month pri­or based on the con­sis­tent­ly meh re­sults baric­i­tinib had pro­duced in Phase III tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER